ASCIA News

  • PBS listings of Dupixent (dupilumab) for uncontrolled severe asthma (1st April 2021) and severe atopic dermatitis (1st March 2021)
    Dupixent (dupilumab) is now listed on the Pharmaceutical Benefits Scheme (PBS) in Australia for the treatment of patients aged 12 years and older with: Uncontrolled severe asthma from 1st April 2021; and Severe atopic dermatitis who have failed to respond to optimally...
  • Virtual Meetings about COVID-19 Vaccines
    The following two online events are being hosted by the peak professional bodies for allergy and immunology in Australia, New Zealand and Asia and registration is free.   ASI-ASCIA COVID-19 Vaccine Safety Online Fireside Chat on Wednesday 31st March 2021, 6.30-7.30pm AEST...
  • Evidence-Based Versus Non Evidence-Based Allergy Tests and Treatments
    Allergy is a science based medical speciality which relies on the use of ‘evidence-based’ allergy tests and treatments. This means that there needs to be published evidence that a test or treatment is reliable, based on studies of other patients with similar conditions. Accurate...
  • New and Updated ASCIA COVID-19 Vaccine FAQs
    The following two new ASCIA COVID-19 Vaccination FAQs have been added to www.allergy.org.au/patients/ascia-covid-19-vaccination-faq, in response to questions about the Pfizer and AstraZeneca COVID-19 vaccines. FAQ 3: Does mRNA which is used in the Pfizer vaccine integrate...
  • International Women's Day
    8 March 2021:  On International Women's Day we celebrate ASCIA's female leadership and members. Pictured left to right: ASCIA Past Presidents Prof Connie Katelaris AM, Prof Jo Douglass and Dr Melanie Wong (now Chair of the Allergy and Immunology Foundation of Australasia) with...
  • Anapen® is TGA approved and recommended by PBAC for PBS Listing
    Anapen 300®, Anapen 500® and Anapen 150 Junior® (Anapen Junior) adrenaline (epinephrine) autoinjectors have been approved by the Therapeutic Goods Administration (TGA) for the treatment of anaphylaxis (severe allergic reactions).  The Pharmaceutical Benefits Advisory...
  • PBS listing of Dupixent (dupilumab) for severe atopic dermatitis
    From 1st March 2021, Dupixent (dupilumab) is listed on the Pharmaceutical Benefits Scheme (PBS) in Australia for the treatment of patients, 12 years and above, with severe atopic dermatitis, who have failed to respond to optimally prescribed topical treatments. Dupixent is a...
  • ASCIA 2021 Conference Update
    The ASCIA 2021 Conference is being hosted as a virtual event from Wednesday 1st to Friday 3rd September 2021. The ASCIA 2021 Conference website is being updated and registration will open in May 2021. In the meantime, a preliminary program summary, registration fees, abstract...
ASCIA Member Login

  • Site updated: 7 Apr 2021


ASCIA Update

Information for the community about allergic diseases, immunodeficiencies and other immune diseases.
See latest edition here...

Join our mailing list here...

AIFA: Donate Now
AIFA: Donate Now
National Allergy Strategy
National Allergy Strategy
ASCIA: WAO Member
ASCIA: WAO Member
About ASCIA

ASCIA is the peak professional body of clinical immunology and allergy in Australia and New Zealand
ASCIA promotes and advances the study and knowledge of allergy and other immune diseases

Quick Links

About ASCIA

ASCIA is a registered trademark of the Australasian Society of Clinical Immunology and Allergy. All content is subject to copyright for the Australasian Society of Clinical Immunology and Allergy. Read more...

The content for the website is developed and approved by ASCIA Committee and ASCIA Working Party Members. Read more...

Disclaimer I Privacy

The ASCIA website is intended for use by ASCIA members, health professionals and the general public. The content provided is for education, communication and information purposes only and is not intended to replace or constitute medical advice or treatments. Read more...

ASCIA respects your privacy. Read our privacy policy here...

Sponsors | Advertising

ASCIA does not endorse products from sponsoring organisations, nor is it influenced by sponsoring organisations with regard to the content of education programs and websites. 

The ASCIA website does not accept advertising. Any link to a third-party website does not imply any endorsement by ASCIA.

Accreditiation

healthdirect

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information: verify here.